Work

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma

Year: 2023

Type: article

Abstract: SUMMARY: In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.

Source: Blood Cancer Discovery

DOI: 10.1158/2643-3230.bcd-23-0176

Authors: Ross Firestone, Alexander M. Lesokhin, Saad Z. Usmani

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute